Wedbush Reiterates Outperform on Larimar Therapeutics, Maintains $11 Price Target
Benzinga Newsdesk 8 months ago
NewsPrice TargetReiterationAnalyst Ratings
Wedbush analyst Laura Chico reiterates Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and maintains $11 price target.
Wedbush analyst Laura Chico reiterates Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and maintains $11 price target.